Shilan Ding
Shilan Ding
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
1,2,3,4,†,
Min Wang
Min Wang
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
1,2,3,4,†,
Song Fang
Song Fang
5
Kunming Shenghuo Pharmaceutical Group Co., Ltd., Kunming, China
5,
Huibo Xu
Huibo Xu
6
Academy of Chinese Medical Sciences of Jilin Province, Jilin, China
6,
Huiting Fan
Huiting Fan
7
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
7,
Yu Tian
Yu Tian
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
1,2,3,4,
Yadong Zhai
Yadong Zhai
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
1,2,3,4,
Shan Lu
Shan Lu
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
1,2,3,4,
Xin Qi
Xin Qi
7
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
7,
Fei Wei
Fei Wei
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
1,2,3,4,
Guibo Sun
Guibo Sun
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
1,2,3,4,*,
Xiaobo Sun
Xiaobo Sun
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
1,2,3,4,*
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
3
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
4
Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China
5
Kunming Shenghuo Pharmaceutical Group Co., Ltd., Kunming, China
6
Academy of Chinese Medical Sciences of Jilin Province, Jilin, China
7
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Edited and reviewed by:
Jia-Bo Wang, Capital Medical University, China
✉*Correspondence: Guibo Sun, sunguibo@126.com; Xiaobo Sun, sun_xiaobo163@163.com
†
Both authors contributed equally to this study and were considered as co-first authors
Received 2024 Sep 30; Accepted 2024 Dec 23; Collection date 2024.
Keywords: chemotherapy-induced thrombocytopenia, thrombopoietin, D-dencichine, platelets, cytokines, mouse
Copyright © 2025 Ding, Wang, Fang, Xu, Fan, Tian, Zhai, Lu, Qi, Wei, Sun and Sun.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.